[Valvular heart disease associated with the treatment of Parkinson disease].
Ergot derivatives (EDs) are used in the treatment of Parkinson's disease, but recent reports indicate induction of valvular heart disease. This survey reviews the documentation and reports on the design of a blinded study of 160 Parkinson's patients treated with either EDs or non-EDs. The present recommendations regarding monitoring of patients treated with ED are also described.
Rasmussen
Vibeke Guldbrand
VG
Arhus Universitetshospital, Skejby Sygehus, Kardiologisk Afdeling. vibeke.guldbrand@svf.au.dk
Dupont
Erik
E
Østergaard
Karen
K
Egeblad
Henrik
H
D000978:Antiparkinson Agents / Q000009:adverse effects*; D018491:Dopamine Agonists / Q000009:adverse effects*; D004879:Ergotamines / Q000009:adverse effects*; D006349:Heart Valve Diseases / Q000139:chemically induced*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D004879:Ergotamines